This could be due to mutations in other genes, such as TP53, which we did not analyze in our study, or increased SIGLEC9 expression may potentially occur at the very early stages of CRC pathogenesis during the induction of primary mutations. This evidence concerns the gene SIGLEC9 and colorectal carcinoma.